Donor‐Derived T‐Cell Redirection With Epcoritamab Achieving Complete Response After Early Post‐Allo‐HSCT Relapse of DLBCL

ABSTRACT Background Epcoritamab, a bispecific CD3×CD20 antibody, offers a promising treatment for relapsed diffuse large B‐cell lymphoma (DLBCL). Its efficacy and safety after allogeneic hematopoietic stem cell transplantation (allo‐HSCT) remain unclear. Case Report In a 64‐year‐old man with relapse...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Yoshikazu Ikoma, Yuto Kaneda, Ryoma Shimazu, Daisuke Okamoto, Takuro Matsumoto, Nobuhiko Nakamura, Hiroshi Nakamura, Nobuhiro Kanemura, Hideko Goto, Naoki Katsumura, Masahito Shimizu
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Wiley 2025-12-01
Serie:	eJHaem
Ämnen:	bispecific antibodies diffuse large B‐cell lymphoma graft‐versus‐host disease haematopoietic stem cell transplantation immunotherapy
Länkar:	https://doi.org/10.1002/jha2.70186
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!